This initiative is designed to help clinicians and other healthcare professionals implement comprehensive treatment strategies to decrease microvascular and macrovascular risks in patients with type 2 diabetes (T2DM).
Upon completion of this activity participants will be able to:
Jaime Davidson, MD
Consulting Agreements/Advisory Board: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Aspire Bariatrics, Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lifescan, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk A/S; Roche Diagnostics; sanofi-aventis U.S. LLC.
Speakers’ Bureau: Janssen Pharmaceuticals, Inc.; Novo Nordisk A/S; Takeda Pharmaceuticals North America, Inc.
All Academy for Continued Healthcare Learning and Indiana University School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through collaboration with Eli Lilly and Company.
This activity is supported by an educational grant from Bristol-Myers Squibb/AstraZeneca LP.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.